COSCIENS Biopharma Management

Management criteria checks 3/4

COSCIENS Biopharma's CEO is Gilles Gagnon, appointed in Jun 2024, has a tenure of less than a year. directly owns 0.98% of the company’s shares, worth €106.00K. The average tenure of the management team and the board of directors is 3.2 years and 0.4 years respectively.

Key information

Gilles Gagnon

Chief executive officer

US$133.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	1.0%
Management average tenure	3.2yrs
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Gilles Gagnon (70 yo)

less than a year

Tenure

US$133,500

Compensation

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Director of COSCIENS Biopharma Inc. (formerly known as Aeterna Zentaris Inc.) since June 03, 2024 and had been its Independent Director since January 1, 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gilles Gagnon	President	less than a year	US$133.50k	0.98% € 106.0k
Giuliano La Fratta	Senior VP of Finance & CFO	2.8yrs	US$254.19k	no data
Michael Teifel	Senior VP of Non-Clinical Development & Chief Scientific Officer	3.5yrs	US$248.24k	no data
Nicola Ammer	Chief Medical Officer & Senior VP of Clinical Development	6.8yrs	US$212.55k	no data
Matthias Gerlach	Senior Vice President Manufacturing and Supply Chain & Head of Production	no data	US$263.11k	no data

3.2yrs

Average Tenure

Experienced Management: ET8's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gilles Gagnon	President	4.8yrs	US$133.50k	0.98% € 106.0k
Genevieve Foster	Independent Director	less than a year	no data	no data
Gerald Batist	Member of the Scientific Advisory Board	no data	no data	no data
Hartmut Michel	Member of the Scientific Advisory Board	no data	no data	no data
Pierre Labbe	Director	less than a year	no data	no data
Ronald Miller	Independent Chairman	no data	no data	no data
Marcel Verheij	Member of the Scientific Advisory Board	no data	no data	no data
René Frydman	Member of the Scientific Advisory Board	no data	no data	no data
Alan DeCherney	Member of the Scientific Advisory Board	no data	no data	no data
Klaus H. Diedrich	Member of the Scientific Advisory Board	no data	no data	no data
Frans M. Debruyne	Member of the Scientific Advisory Board	no data	no data	no data
Ulf Rapp	Member of the Scientific Advisory Board	no data	no data	no data

0.4yrs

Average Tenure

Experienced Board: ET8's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.

COSCIENS Biopharma Management

Management criteria checks 3/4

Key information

Recent management updates

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Recent updates

Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023)

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings released: US$0.022 loss per share (vs US$0.015 loss in 1Q 2021)

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: US$0.073 loss per share (vs US$0.13 loss in FY 2020)

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: €1.55

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: €0.60

New 90-day high: €0.37

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

New 90-day high: €0.35

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: €0.28

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

New 90-day low: €0.28

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low - €0.34

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

New 90-day low - €0.35

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure